The overall long term goal of this Imaging Core is to identify structural, perfusion, and metabolic changes in the brain that predict future cognitive decline and conversion to dementia. The overall approach will be to initially study healthy elders ands age/gender matched patients with well-characterized dementia associated with Alzheimer's disease and Frontotemporal dementia using a newly acquired 4 Tesla Bruker/Siemens MRI/MRS scanner, which will be optimized for investigation of neurodegenerative disease. These initial studies will provide imaging characteristics of established dementia. We will also study a group of subjects with MCl-Peterson criteria. In subsequent years we will study increasing numbers of subjects with MCI subtypes and MCl-Peterson who likely represent early stages of AD and FTD and who are expected to ultimately convert to dementia. All subjects will be recruited and evaluated by the Clinical Core.

Public Health Relevance

Alzheimer's disease affects millions of Americans, and the incidence and prevalence are growing as people get older. MRI imaging provides unique information concerning the changes in the brain which occur in demented subjects, as well as in the early stages of the disease. Imaging also helps identify other processes which lead to cognitive impairment. Thus, state of the art imaging is a critical aspect of this ADRC.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG023501-10
Application #
8458090
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
10
Fiscal Year
2013
Total Cost
$128,045
Indirect Cost
$46,278
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Tan, Chin Hong; Fan, Chun Chieh; Mormino, Elizabeth C et al. (2018) Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition. Acta Neuropathol 135:85-93
Mok, Sue-Ann; Condello, Carlo; Freilich, Rebecca et al. (2018) Mapping interactions with the chaperone network reveals factors that protect against tau aggregation. Nat Struct Mol Biol 25:384-393
Sturm, Virginia E; Brown, Jesse A; Hua, Alice Y et al. (2018) Network Architecture Underlying Basal Autonomic Outflow: Evidence from Frontotemporal Dementia. J Neurosci 38:8943-8955
Erkkinen, Michael G; Zúñiga, Raquel Gutiérrez; Pardo, Cristóbal Carnero et al. (2018) Artistic Renaissance in Frontotemporal Dementia. JAMA 319:1304-1306
Bonham, Luke W; Geier, Ethan G; Steele, Natasha Z R et al. (2018) Insulin-Like Growth Factor Binding Protein 2 Is Associated With Biomarkers of Alzheimer's Disease Pathology and Shows Differential Expression in Transgenic Mice. Front Neurosci 12:476
Schneider, Raphael; McKeever, Paul; Kim, TaeHyung et al. (2018) Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. J Neurol Neurosurg Psychiatry 89:851-858
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10
Karch, Celeste M; Wen, Natalie; Fan, Chun C et al. (2018) Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum. JAMA Neurol 75:860-875
Scheltens, Nienke M E; Tijms, Betty M; Heymans, Martijn W et al. (2018) Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression. J Alzheimers Dis 65:1029-1039

Showing the most recent 10 out of 590 publications